Worldquant Millennium Advisors LLC Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Worldquant Millennium Advisors LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 214,815 shares of the medical equipment provider's stock after purchasing an additional 30,645 shares during the period. Worldquant Millennium Advisors LLC owned 0.10% of Hologic worth $15,486,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Woodline Partners LP raised its position in Hologic by 14.3% during the 4th quarter. Woodline Partners LP now owns 144,072 shares of the medical equipment provider's stock valued at $10,386,000 after purchasing an additional 18,072 shares during the last quarter. Squarepoint Ops LLC raised its position in Hologic by 657.8% during the 4th quarter. Squarepoint Ops LLC now owns 264,800 shares of the medical equipment provider's stock valued at $19,089,000 after purchasing an additional 229,858 shares during the last quarter. Two Sigma Advisers LP raised its position in Hologic by 78.2% during the 4th quarter. Two Sigma Advisers LP now owns 31,000 shares of the medical equipment provider's stock valued at $2,235,000 after purchasing an additional 13,600 shares during the last quarter. Tidal Investments LLC raised its position in Hologic by 38.3% during the 4th quarter. Tidal Investments LLC now owns 21,223 shares of the medical equipment provider's stock valued at $1,530,000 after purchasing an additional 5,872 shares during the last quarter. Finally, State of Wyoming raised its position in Hologic by 210.1% during the 4th quarter. State of Wyoming now owns 7,335 shares of the medical equipment provider's stock valued at $529,000 after purchasing an additional 4,970 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on HOLX shares. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Evercore ISI decreased their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada decreased their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Finally, Raymond James reissued an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $77.42.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.88% of the company's stock.

Hologic Stock Down 0.4%

HOLX stock traded down $0.20 on Friday, reaching $54.28. 2,268,541 shares of the company traded hands, compared to its average volume of 2,144,938. The firm has a fifty day simple moving average of $58.17 and a 200-day simple moving average of $66.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a market cap of $12.10 billion, a P/E ratio of 17.12, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the business posted $1.03 EPS. The company's revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.